Civica Rx

Rule Changes

As of May 2026: Building a $140 million sterile injectable facility in Petersburg, Virginia; drugs expected to reach market in 2026

Only 9% of the factories making active pharmaceutical ingredients for American medicines are in the U.S.; China and India account for roughly two-thirds. For decades, this arrangement kept drug prices low and went largely unchallenged, until the COVID-19 pandemic exposed how quickly a foreign export ban could empty American pharmacy shelves. The FDA is assembling three programs to reverse this dependency: PreCheck to accelerate new factory buildouts, priority reviews for domestically made generics, and a proposed three-year fee waiver for new domestic plants under the next Generic Drug User Fee Amendments (GDUFA) reauthorization.

Updated May 29

Rule Changes

As of May 2026: Distributing affordable insulin as of January 2026

On January 1, 2026, nonprofit Civica Rx launched insulin glargine pens at $55 a box; California debuted its CalRx-branded insulin the same day at the same price. Both undercut branded products by up to 90%: no insurance forms, no rebates, no hidden markups, just one transparent price for anyone, in a market three pharmaceutical giants control with a 90% share.

Updated May 19